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minants of which include severity of PD, wearing-off symp-
toms, dosage of antiparkinsonian drugs and sleep-disor-
dered breathing.  Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Excessive daytime sleepiness (EDS) is common, al-
though often underestimated in patients with Parkin-
son’s disease (PD). An Epworth Sleepiness Scale score 
(ESS) above 10, indicating subjective EDS, has been re-
ported in up to 50% of patients with PD  [1] . Frucht et al. 
 [2] and other authors have reported sudden sleep epi-
sodes (‘sleep attacks’) causing driving accidents in PD pa-
tients taking non-ergot dopamine agonists. Severe EDS, 
defined as mean sleep latency (MSL) on the Multiple 
Sleep Latency Test (MSLT)  ! 5 min, has been reported in 
about 20% of unselected patients with PD  [3, 4] and in up 
to 50% of PD patients with EDS  [5] . Data on the frequen-
cy of sleep onset REM (SOREM) have been variable. 
SOREM was found in 29–39% of PD patients with EDS 
 [5, 6] and in up to 70% of PD patients with hallucinations 
 [7] . SOREM was also observed in a case of juvenile PD  [8] 
and in 20–28% of unselected PD patients  [4, 9, 10] . Others 
have reported a less frequent occurrence of SOREM in 
PD and other forms of parkinsonism  [11] .
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 Abstract 
 Background/Aims: Excessive daytime sleepiness (EDS) is 
frequent in patients with Parkinson’s disease (PD). Occasion-
ally, EDS in PD exhibits narcolepsy-like features. We aimed to 
assess characteristics and determinants of EDS in consecu-
tive patients with PD.  Methods: Thirty consecutive patients 
with PD underwent a detailed clinical examination. EDS was 
assessed using the Epworth Sleepiness Scale (ESS) and Mul-
tiple Sleep Latency Test (MSLT). Sleep was assessed using 
video-polysomnography. Cerebrospinal fluid (CSF) hypocre-
tin-1 levels were obtained in 3 patients.  Results: ESS was  1 10 
in 17 patients (57%). Mean sleep latency (MSL) on MSLT was 
 ! 5 min in 11 patients (37%). There was a significant negative 
correlation between ESS and MSL. None of the 11 patients 
with MSL  ! 5 min showed a sleep onset REM (SOREM) epi-
sode. Patients with EDS had higher dopamine agonists/le-
vodopa equivalent doses, higher apnea/hypopnea index 
and exhibited wearing-off symptoms more often. Hypocre-
tin-1 was normal in 3 patients tested.  Conclusion: EDS, which 
can sometimes be severe, is common in PD patients even in 
the absence of SOREM and detectable CSF-hypocretin defi-
ciency. In PD, EDS is a multifaceted phenomenon, the deter-
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 Subjective (as assessed by ESS) and objective (as as-
sessed by MSLT) EDS in PD was systematically examined 
in 8 studies. In 6 studies, consecutive unselected PD pa-
tients were included  [3, 4, 9, 10, 12, 13] . In 2 studies, only 
PD patients referred for sleepiness or with ESS  1 10 were 
examined  [5, 6] . Various factors including age  [14, 15] , 
gender  [1, 16] , dopaminergic treatment  [9, 17, 18] , severity 
of PD  [18, 19] and night-time sleep disturbances  [5, 12] 
have been discussed as causes of EDS in PD. Neurons 
producing hypocretin (a hypothalamic protein involved 
in sleep-wake regulation, food intake and reward mecha-
nism) were recently shown to be reduced in PD  [20, 21] . 
Low cerebrospinal fluid (CSF) hypocretin-1 levels were 
found in 1 study assessing severe idiopathic PD patients 
 [22] , but were not confirmed in 3 subsequent studies  [11, 
23, 24] .
 The aim of this study was to assess, by means of a mul-
timodal approach, the characteristics and potential de-
terminants of EDS in a nonselected population of PD pa-
tients.
 Patients and Methods 
 Daytime sleepiness and night-time sleep was assessed in 30 
unselected consecutive patients (24 men; mean age 65  8 10 years 
SD) with idiopathic PD, diagnosed according to the UK PD Brain 
Bank criteria  [25] . The study was approved by the local ethics 
committee and all patients gave informed written consent prior 
to the study. Based on their characteristics, these patients were 
similar to 194 PD patients seen in our outpatient clinic for move-
ment disorders over a 2-year period (2005–2006;  table 1 ).
 The mean disease duration at the time of the polysomnogra-
phy/MSLT was 8.2 years (SD 6.6 years), ranging from 1 month to 
29 years. The mean Unified Parkinson’s Disease Rating Scale part 
III (UPDRS III, motor score) was 25 (SD 10, range 7–44) in ‘on’ 
condition and the mean Hoehn and Yahr (HY) stage was 2.5 (SD 
0.9, range 1–4). Fourteen patients had advanced PD (HY  6 3), of 
whom 4 patients suffered from severe PD (HY = 4). Sixteen of the 
30 patients reported a depressed mood, 16 patients had memory 
difficulties, 11 had wearing-off symptoms, 8 had peak-dose dys-
kinesia and 8 experienced visual hallucinations. Antiparkinso-
nian drugs included levodopa (n = 22), non-ergot (pramipexole 
and ropinirole) and ergot (pergolide, cabergoline) derivatives
(n = 16), apomorphine (n = 1), COMT inhibitors (n = 5), amanta-
dine (n = 5), and anticholinergics (n = 3). The mean levodopa 
equivalent dose was 651 mg (SD 531, range 0–2,011). Six patients 
were taking sleeping pills and 10 patients were taking antidepres-
sants.
 Subjective sleepiness was assessed using ESS. All patients un-
derwent standard nocturnal video-polysomnography consisting 
of 4 channel EEGs (C3/A2, C4/A1, O1/A2, O2/A1), left and right 
electro-oculography, submental electromyography, electrocardi-
ography, respiratory flow (using a nasal cannula) and effort (using 
Medcare XactTrace respiratory inductive plethysmography tech-
nology belts), pulse oximetry, and left and right anterior tibialis 
electromyography. All recordings were done on Medcare Somno-
logica Studio. Sleep stages, periodic limb movements and arousals 
were scored manually according to international criteria  [26–28] . 
Apnea and hypopnea were scored according to the recommenda-
tions of the American Academy of Sleep Medicine  [29] , but dif-
fering in that a desaturation of 4% instead of 3% was needed when 
the amplitude decrease did not reach 50%. Sleep onset was de-
fined as the first epoch of either NREM 2 or REM sleep.
 On the day following the nocturnal recording, standard MSLT 
 [30] was performed, starting 2 hours after waking up. For each 
patient, 4 (n = 20) or 5 (n = 5) naps, each with a duration of 20 min 
in 2-hour intervals were recorded. Sleep onset was defined as the 
first epoch of any sleep stage, including stage 1. The naps were 
terminated after 20 min. After each nap, the patients were asked 
to estimate if they had fallen asleep or not.
 The hypocretin level in CSF was measured in 3 patients.
 Statistical analysis was performed using SPSS 15 software.   2 
tests, t tests, repeated measures ANOVA and Mann-Whitney tests 
were used to analyze categorical and continuous variables. Pear-
son’s correlation was used to measure the degree of association 
between MSL, ESS, subjectively reported sleep duration, night-
time sleep parameters, levodopa equivalent dose, disease severity 
and duration. The significance level was set at p  ! 0.05.
Table 1. Main demographic and clinical characteristics of 30 patients with Parkinson’s disease included in the 
study and 194 patients with PD, seen in the outpatient’s clinic for movement disorders over 2 years
 Patients with assessment of
sleep and sleepiness (n = 30)
Outpatients
(n = 194)
p
Age, years 65810 (45–78) 67810 (36–89) NS
Disease duration, years 8.286.6 (0–29) 8.586.6 (0–29) NS
UPDRS III 25810 (7–44) 24812 (4–74) NS
Hoehn and Yahr Stage 2.580.9 (1–4) 2.581 (1–4) NS
Dopamine agonist equivalent dose, mg 2058230 (0–700) 2118218 (0–1,000) NS
Levodopa equivalent dose, mg 6518531 (0–2,011) 6328436 (0–2,140) NS
Values are means 8 SD (range). UPDRS III = Unified Parkinson’s Disease Rating Scale part III.
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 Results 
 The data on ESS, polysomnography and MSLT of the 
entire population are presented in  table 2 .
 Sleep-disordered breathing [apnea/hypopnea index 
(AHI)  1 10/h] was found in 10 patients (33% of the entire 
population), and was severe (AHI  1 30) in 5 of them. In 2 
of these patients, CPAP treatment was previously at-
tempted but not tolerated. In 3 patients, the apneas were 
mostly of central origin.
 Periodic limb movements in sleep ( 1 10/h) was found 
in 5 (17% of the entire population).
 Subjective Sleepiness (ESS) 
 Seventeen patients (57% of the entire population) re-
ported subjective EDS (ESS  1 10). In 7 patients (23%), EDS 
was severe and ‘narcolepsy like’ (ESS  6 14)  [31] .
 Patients with EDS had a significantly higher dopa-
mine agonist dose, higher levodopa equivalent dose, 
shorter night-time sleep latency and shorter MSL on 
MSLT than patients without EDS ( table 3 ). Additionally, 
a trend towards a lower nocturnal percentage of REM 
sleep was observed. No significant differences were ob-
served regarding age, gender, disease duration and sever-
ity (as expressed by UPDRS III and HY stage), or other 
polysomnographic sleep parameters. ESS did not corre-
late with the subjectively reported sleep duration at 
home.
 Objective Sleepiness (MSL on MSLT) 
 The MSL on MSLT was 9.2 min (SD 6.4, range 0.3–20). 
Eleven patients (37%) had severe objective EDS, which is 
a MSL  ^  5 min. In 53 of 125 nap opportunities (42%), the 
sleep latency was  ^  5 min. Sixteen patients had at least 1 
nap with a sleep latency  ^  5 min. From the 11 patients 
with a MSL  ^  5 min, in 7 patients, all naps had a sleep 
latency  ^  5 min (4 of 4 naps in 6 patients, and 5 of 5 naps 
in 1 patient); in 3 patients, 3 out of 4 naps were with a sleep 
latency  ^  5 min; and in 1 patient, 2 out of 4 naps were 
with a sleep latency of  ^  5 min. Repeated measures ANO-
VA showed no significant difference between the mean 
duration of the naps, regardless of the time of the test 
(data sphericity was not violated, p = 0.75, F 3 = 0.406). The 
distribution of naps with sleep latency  ^  5 min was as fol-
lows: 15/30 in the 1st nap, 10/30 in the 2nd nap, and 13/30 
in both the 3rd and 4th nap. These frequencies were not 
significantly different (Pearson   2 , p = 0.63). There were 
5 patients with a 5th nap (in one of them sleep latency was 
 ^  5 min) and the mean duration of the 5th nap did not 
differ from the first 4 naps ( table 4 ).
Table 2. ESS, polysomnographic and MSLT data in 30 consecutive 
patients with PD
 Mean 8 SD Range
ESS score 1085 0–17
Subjective night-time sleep duration, h 6.581.9 2–10
Total sleep time, min 314866 165–421
Nocturnal sleep latency in PSG, min 35846 2–227
Sleep efficiency, % 79816 28–98
REM latency, min 118887 26–378
NREM 1, % 1285 1–24
NREM 2, % 43.4814 12–81
Slow wave sleep, % 1289 0.1–33
REM, % 1287 0–27
AHI 15821 0–63
PLMS index 10822 0–81
Mean sleep latency in MSLT, min 9.286.4 0.3–20
PSG = Polysomnography; AHI = apnea/hypopnea index; 
PLMS = periodic leg movement in sleep.
Table 3. PD patients with (ESS >10) and without subjective EDS
 ESS >10
(n = 17)
ESS ≤10
(n = 13)
p
Nocturnal sleep latency, min 19828 57856 0.021
REM, % 1086 1487 0.087
Mean sleep latency in MSLT, min 685 1386 0.005
Dopamine agonist equivalent
dose, mg 3108226 688155 0.003
Levodopa equivalent dose, mg 8368426 4088573 0.026
Only statistically significant results and trends are shown.
Table 4. Mean duration of the naps and number of naps with a 
sleep latency ≤5 min depending on the time of the test
Nap No. Patients, n Mean 8 SD Naps with a
SL ≤5 min, n
Nap 1 30 9.187.5 15
Nap 2 30 9.687.2 10
Nap 3 30 8.587.1 13
Nap 4 30 8.987.2 13
Nap 5 5 8.186.4 1
Repeated measures ANOVA p = 0.75, F3 = 0.406; 2 p = 0.63. 
SL = Sleep latency. Because of the small number of patients with 
a 5th nap these data were not included in the repeated measures 
ANOVA analysis and the 2 statistics.
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 A significant correlation between the subjectively re-
ported sleep duration at home and MSL was observed 
only in the patients with ESS  1 10 (r = 0.531, p = 0.034).
 A highly significant negative correlation was found 
between ESS and the MSL in MSLT (r = –0.65, p  ! 0.001; 
 fig. 1 ).
 Patients with MSL  ! 5 min had significantly shorter 
nocturnal sleep latency, higher ESS scores and a higher 
AHI when compared to patients with MSL  1 5 min ( ta-
ble 5 ). A trend towards a higher dopamine agonist equiv-
alent dose was also observed. No significant differences 
were observed regarding age, gender, disease duration 
and severity (as expressed by UPDRS III and HY stage), 
other polysomnographic sleep parameters, or overall le-
vodopa equivalent dose.
 In 15 patients (50%), a sleep-wake misperception was 
present: 10 patients (33%) did not realize they fell asleep 
(sleep-state misperception) in at least 1 nap, and the oth-
er 5 (17%) thought they fell asleep although they did not 
(wake-state misperception). Patients with sleep-state 
misperception did not differ from the rest of the popula-
tion studied regarding ESS, MSL, night-time parameters, 
demographic characteristics, disease duration or severi-
ty. Patients with wake-state misperception had signifi-
cantly longer MSL (17.2  8 3.8 min) in comparison to the 
rest of the population (7.5  8 5.6 min, p  ! 0.001). Five pa-
tients with ESS  1 10 had normal MSL in MSLT ( 1 8 min) 
and only 1 patient with short MSL (5.6 min) had a normal 
ESS (5/24 points).
 No correlation was observed between ESS or MSL and 
age.
 SOREM was not recorded in any test in any of the 11 
patients with MSL  ^  5 min who slept for 15 min after 
sleep onset. As the naps were terminated after 20 min, 
SOREM in the rest of the patients is not reported.
 No significant differences regarding ESS, MSL and 
night-time parameters were observed between patients 
with advanced/severe (HY  6 3, n = 14) and beginning/
light (HY  ! 3, n = 16) PD.
 Eight patients reported hallucinations. Patients with 
hallucinations had significantly higher UPDRS III 
scores (33  8 9 vs. 21  8 9, p = 0.004), especially when 
tremor-related points were excluded (33  8 9 vs. 19  8 
10, p = 0.002), had a higher HY stage (3.1  8 0.8 vs. 2.3 
 8 0.9, p = 0.033) and less REM sleep (6.2  8 7.5 vs. 13.7 
 8 5.6%, p = 0.006). They tended to be objectively sleep-
ier during the day than the patients without hallucina-
tions (MSL in patients with hallucinations 5.8  8 5.9 
min, without hallucinations 10.4  8 6.3 min, mean  8 
SD, p = 0.081) and fall asleep faster at night (night-time 
sleep latency in patients with hallucinations 13.9  8 11.1 
min, without hallucinations 43.3  8 51.5 min, mean  8 
SD, p = 0.07).
 Patients with wearing-off symptoms (n = 11) had low-
er MSL (5.9  8 5.8 vs. 11  8 6.1, p  ! 0.031), a higher HY 
stage (2.9  8 0.9 vs. 2.2  8 0.9, p = 0.047), longer therapy 
duration (9.9  8 5.2 vs. 4.7  8 6.9 years, p = 0.04), a high-
er dopamine agonist equivalent dose (330  8 256 vs. 132 
 8 183 mg, p = 0.02) and a higher levodopa equivalent 
dose (1,034  8 457 vs. 429  8 445 mg, p = 0.001) when 
compared to patients without wearing-off symptoms.
 Both ESS and MSL correlated significantly with noc-
turnal sleep latency, dopamine agonist equivalent dose 
0
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 Fig. 1. Correlation between ESS and MSL in MSLT (r = –0.65, p  ! 
0.001). 
Table 5. PD patients with (MSL ≤5 min) and without severe objec-
tive EDS
 MSL ≤5
(n = 11)
MSL >5
(n = 19)
p
ESS score 1482 885 0.001
Nocturnal sleep latency in PSG, min 1189 50853 0.001
AHI 24826 9815 0.026
Dopamine agonist equivalent dose
mg 3068216 1468222 0.066
Only significant results and trends are shown.
MSL = Mean sleep latency on MSLT; PSG = polysomnography.
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and AHI. ESS also correlated with levodopa equivalent 
dose and MSL to the percentage of REM sleep. No cor-
relation was found with other nocturnal sleep parameters 
or disturbances, motor functioning (as expressed by
UPDRS III in ‘on’ condition), disease duration or severity 
(as expressed by HY stage;  table 6 ).
 CSF Hypocretin-1 Levels 
 Hypocretin-1 level in CSF was measured in 3 patients 
and was in the normal range in all of them (low  ! 110 pg/
ml, intermediate 110–200 pg/ml, normal  1 200 pg/ml) 
 [32] .
 The 1st patient denied having hallucinations, his ESS 
was 11, his MSL was 5.5 min and CSF hypocretin-1 levels 
were 454 pg/ml. The 2nd patient was a woman who re-
peatedly complained of EDS (ESS 13), but no sleep was 
registered in MSLT. She did not report hallucinations and 
her hypocretin level was normal at 519 pg/ml. The other 
patient also complained of EDS (ESS 12), had MSL of
5 min, and no SOREM was registered. He did not report 
hallucinations and his hypocretin in CSF was 260 pg/
ml.
 Discussion 
 Subjective and objective EDS are common in PD. Its 
main determinants include motor complications such as 
wearing-off symptoms, the dosage of antiparkinsonian 
drugs and sleep-disordered breathing. Severe, ‘narcolep-
sy-like’ EDS can be observed in PD even in the absence 
of SOREM and a detectable CSF hypocretin-1 deficit. 
However, PD patients tended to overestimate their sleep-
iness, as there were more patients (n = 5) with subjective 
sleepiness (ESS  1 10) and normal results in the objective 
test (normal MSL in MSLT), and only 1 patient with ob-
jective sleepiness (shortened MSL  ! 5 min) and a normal 
ESS score.
 Frequency and Characteristics of EDS in PD 
 Subjective (ESS  1 10 in 57%) and objective EDS (MSL 
in MSLT  ! 5 min in 37%) were common in this PD popu-
lation. Similar percentages were reported in previous 
studies  [1, 3, 4] , including those with unselected PD pa-
tients. As already reported in the literature  [33, 34] , we 
did not find an association between EDS and age. Sev-
eral studies have suggested a higher frequency of EDS in 
male PD patients  [1, 16] . In our sample, however, no gen-
der differences were found.
 An association between EDS and SOREM has been 
reported. Healthy subjects with multiple SOREMs were 
sleepier  [35–37] than subjects with 1 or no SOREM. None 
of the 11 patients with MSL  ^  5 min presented with 
SOREM. Because naps were terminated after 20 min (in-
stead of allowing the patients to sleep at least 15 min after 
sleep onset), we do not report on the occurrence of 
SOREM in the rest of the patients.
 Sleep-misperception was observed in 10 patients (33%), 
which is similar to previous reports in which sleep-state 
misperception in association with MSLT naps was re-
ported in up to 38% of patients with PD and in 45% of 
patients with EDS  [38] . In healthy subjects, sleep percep-
tion depends on sleep duration; after a 4-min nap, only 
50% of healthy controls confirmed they had fallen asleep 
 [39] . In a previous study, the patients with sleep misper-
ception tended to underestimate their sleepiness in ESS 
 [38] . No specific characteristics of PD with sleep misper-
ception were found in our series.
 There were also 5 patients who did not realize they fell 
asleep in at least 1 nap. These patients had longer mean 
sleep latencies on MSLT when compared to the rest of the 
study population. However, PD patients tended to over-
estimate their sleepiness, as there were more patients
(n = 5) with subjective sleepiness (ESS  1 10) and normal 
results in the objective test (normal MSL in MSLT), and 
only 1 patient with objective sleepiness (shortened MSL 
 ! 5 min) and a normal ESS score.
 As already shown by others  [10] , ESS correlated sig-
nificantly with MSL. This supports the use of ESS as a 
screening tool in clinical practice for EDS in PD pa-
tients.
Table 6. Significant associations with subjective (ESS) or objec-
tive [mean sleep latency (MSL) in MSLT] measures of EDS
ESS MSL
r p r p
Hoehn and Yahr stage 0.074 0.698 –0.063 0.741
UPDRS III –0.082 0.673 0.091 0.640
Total sleep time 0.067 0.725 –0.150 0.427
Sleep efficiency in PSG –0.205 0.277 0.052 0.785
Sleep latency, min –0.599 <0.001 0.581 0.001
REM, % –0.345 0.062 0.393 0.032
AHI 0.392 0.032 –0.347 0.042
Dopamine agonist equivalent
dose, mg 0.562 0.001 –0.484 0.007
Levodopa equivalent dose, mg 0.392 0.032 –0.348 0.059
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 Determinants of EDS in PD 
 Levodopa equivalent dose, sleep-disordered breath-
ing, wearing-off phenomena and REM sleep amount 
during polysomnography were linked to EDS in our 
study (see below).
 EDS and Neurodegeneration (PD Severity) 
 The neurodegenerative process itself has been impli-
cated in the pathophysiology of EDS in PD. Longer dis-
ease duration  [1, 40] and association with UPDRS III  [41] 
and the HY stage  [14, 18, 41] have been reported. In our 
series, patients with advanced/severe PD (HY  6 3) did 
not differ from patients with light/beginning PD (HY 
 ! 3). However, patients with motor fluctuations – a sign 
of advanced PD – had significantly lower mean sleep la-
tencies on MSLT. This may be related to the involvement, 
usually later in the course of PD, not only of the nigro-
striatal dopaminergic system but also of extrastriatal do-
paminergic and non-dopaminergic neurons in the lower 
brainstem and midbrain  [42] involved in sleep-wake reg-
ulation  [43, 44] .
 EDS and Treatment 
 We found a dose-dependent effect for both dopamine 
agonists and the overall levodopa equivalent dose on 
EDS, but not for levodopa alone. Others have similarly 
shown that dopamine agonists  [45] and the total levodo-
pa equivalent dose  [3, 14] are associated with EDS. Ad-
ditionally, patients on levodopa monotherapy had lower 
risk for sleep attacks than patients on dopamine agonist 
monotherapy or patients on a combination of levodopa 
and a dopamine agonist  [16] . Patients with sleep episodes 
while driving had a higher levodopa equivalent dose than 
those without  [46] . In 15 untreated patients with PD, ESS 
increased and MSL decreased significantly after initia-
tion of levodopa treatment  [9] . These findings suggest 
that both the use of dopamine agonists and the levodopa 
equivalent dose are associated with excessive daytime 
sleepiness.
 EDS and Polysomnographic Findings 
 In our series, 3 polysomnographic parameters (sleep 
latency, AHI, sleep latency, REM-sleep amounts) were 
linked to EDS.
 Sleep latencies (at night and during the day) are mark-
ers of sleep propensity. Patients with shorter sleep latency 
at night also had shorter MSL during the day (during 
MSLT) and higher ESS scores, as partially shown by oth-
ers  [3, 4] .
 Sleep-disordered breathing (AHI  6 10) was found in 
one third of our patients. Compared to patients without 
sleep-disordered breathing, this group had lower mean 
sleep latencies on MSLT, but similar ESS. Sleep-related 
breathing disorders may, therefore, contribute to EDS in 
PD patients, very likely without representing its main 
cause in most cases  [5, 12] . In 2 of our patients, CPAP was 
attempted, but not tolerated.
 EDS and CSF Hypocretin-1 Levels 
 CSF hypocretin-1 level was measured in 3 of our pa-
tients and was in the normal range, confirming that EDS 
in PD may be severe even in the absence of a detectable 
hypocretin deficiency  [11, 23, 24] .
 Conclusion 
 Subjective and objective EDS are common in PD pa-
tients. Wearing-off symptoms, dosage of antiparkinso-
nian drugs and sleep-disordered breathing (but not age, 
gender or disease duration) are linked with EDS in PD 
patients. Severe, ‘narcolepsy-like’ EDS can be observed in 
PD even in the absence of SOREM and a detectable CSF 
hypocretin-1 deficit.
 Acknowledgment 
 We thank Esther Werth, PhD, for her help with the sleep-wake 
tests. 
 References  1 Ondo WG, Dat Vuong K, Khan H, Atassi F, 
Kwak C, Jankovic J: Daytime sleepiness and 
other sleep disorders in Parkinson’s disease. 
Neurology 2001; 57: 1392–1396. 
 2 Frucht S, Rogers JD, Greene PE, Gordon MF, 
Fahn S: Falling asleep at the wheel: motor ve-
hicle mishaps in persons taking pramipexole 
and ropinirole. Neurology 1999; 52: 1908–
1910. 
 3 Razmy A, Lang AE, Shapiro CM: Predictors 
of impaired daytime sleep and wakefulness 
in patients with Parkinson disease treated 
with older (ergot) vs newer (nonergot) dopa-
mine agonists. Arch Neurol 2004; 61: 97–
102. 
 4 Rye DB, Bliwise DL, Dihenia B, Gurecki P: 
FAST TRACK: daytime sleepiness in Par-
kinson’s disease. J Sleep Res 2000; 9: 63–69. 
 5 Arnulf I, Konofal E, Merino-Andreu M, et al: 
Parkinson’s disease and sleepiness: an inte-
gral part of PD. Neurology 2002; 58: 1019–
1024. 
 Excessive Daytime Sleepiness in 
Parkinson’s Disease  
Eur Neurol 2010;63:129–135 135
 6 Roth T, Rye DB, Borchert LD, et al: Assess-
ment of sleepiness and unintended sleep in 
Parkinson’s disease patients taking dopa-
mine agonists. Sleep Med 2003; 4: 275–280. 
 7 Arnulf I, Bejjani BP, Garma L, et al: Halluci-
nations, REM sleep, and Parkinson’s disease: 
a medical hypothesis. Neurology 2000; 55: 
 281–288. 
 8 Rye DB, Johnston LH, Watts RL, Bliwise DL: 
Juvenile Parkinson’s disease with REM sleep 
behaviour disorder, sleepiness, and daytime 
REM onset. Neurology 1999; 53: 1868–1870. 
 9 Kaynak D, Kiziltan G, Kaynak H, Benbir G, 
Uysal O: Sleep and sleepiness in patients 
with Parkinson’s disease before and after do-
paminergic treatment. Eur J Neurol 2005; 12: 
 199–207. 
 10 Monaca C, Duhamel A, Jacquesson JM, et al: 
Vigilance troubles in Parkinson’s disease: a 
subjective and objective polysomnographic 
study. Sleep Med 2006; 7: 448–453. 
 11 Baumann C, Ferini-Strambi L, Waldvogel D, 
Werth E, Bassetti CL: Parkinsonism with ex-
cessive daytime sleepiness – a narcolepsy-
like disorder? J Neurol 2005; 252: 139–145. 
 12 Stevens S, Cormella CL, Stepanski EJ: Day-
time sleepiness and alertness in patients with 
Parkinson disease. Sleep 2004; 27: 967–972. 
 13 Shpirer I, Miniovitz A, Klein C, et al: Exces-
sive daytime sleepiness in patients with Par-
kinson’s disease: a polysomnography study. 
Mov Disord 2006; 21: 1432–1438. 
 14 Pal S, Bhattacharya KF, Agapito C, Chaud-
huri KR: A study of excessive daytime sleep-
iness and its clinical significance in three 
groups of Parkinson’s disease patients taking 
pramipexole, cabergoline and levodopa 
mono and combination therapy. J Neural 
Transm 2001; 108: 71–77. 
 15 Gjerstad MD, Alves G, Wentzel-Larsen T, 
Aarsland D, Larsen JP: Excessive daytime 
sleepiness in Parkinson disease: is it the 
drugs or the disease? Neurology 2006; 67: 
 853–858. 
 16 Paus S, Brecht HM, Koster J, Seeger G, Klock-
gether T, Wullner U: Sleep attacks, daytime 
sleepiness, and dopamine agonists in Par-
kinson’s disease. Mov Disord 2003; 18: 659–
667. 
 17 Fabbrini G, Barbanti P, Aurilia C, Vanacore 
N, Pauletti C, Meco G: Excessive daytime 
sleepiness in de novo and treated Parkinson’s 
disease. Mov Disord 2002; 17: 1026–1030. 
 18 O’Suilleabhain PE, Dewey RB Jr: Contribu-
tions of dopaminergic drugs and disease se-
verity to daytime sleepiness in Parkinson 
disease. Arch Neurol 2002; 59: 986–989. 
 19 Diederich NJ, Vaillant M, Mancuso G, Lyen 
P, Tiete J: Progressive sleep ‘destructuring’ in 
Parkinson’s disease. A polysomnographic 
study in 46 patients. Sleep Med 2005; 6: 313–
318. 
 20 Thannickal TC, Lai YY, Siegel JM: Hypocre-
tin (orexin) cell loss in Parkinson’s disease. 
Brain 2007; 130: 1586–1595. 
 21 Fronczek R, Overeem S, Lee SY, et al: Hypo-
cretin (orexin) loss in Parkinson’s disease. 
Brain 2007; 130: 1577–1585. 
 22 Drouot X, Moutereau S, Nguyen JP, et al: Low 
levels of ventricular CSF orexin/hypocretin 
in advanced PD. Neurology 2003; 61: 540–
543. 
 23 Overeem S, van Hilten JJ, Ripley B, Mignot 
E, Nishino S, Lammers GJ: Normal hypocre-
tin-1 levels in Parkinson’s disease patients 
with excessive daytime sleepiness. Neurolo-
gy 2002; 58: 498–499. 
 24 Yasui K, Inoue Y, Kanbayashi T, Nomura T, 
Kusumi M, Nakashima K: CSF orexin levels 
of Parkinson’s disease, dementia with Lewy 
bodies, progressive supranuclear palsy and 
corticobasal degeneration. J Neurol Sci 2006; 
 250: 120–123. 
 25 Gibb WR, Lees AJ: The relevance of the Lewy 
body to the pathogenesis of idiopathic Par-
kinson’s disease. J Neurol Neurosurg Psychi-
atry 1988; 51: 745–752. 
 26 Rechtschaffen A, Kales A: A Manual of Stan-
dardized Terminology, Techniques and 
Scoring System for Sleep Stages of Human 
Subjects. Los Angeles, UCLA Brain Informa-
tion Service/Brain Research Institute, 1968. 
 27 EEG arousals: scoring rules and examples. A 
preliminary report from the Sleep Disorders 
Atlas Task Force of the American Sleep Dis-
orders Association. Sleep 1992; 15: 174–184. 
 28 American Academy of Sleep Medicine: In-
ternational Classification of Sleep Disorders: 
Diagnostic and Coding Manual, ed 2., West-
chester, American Academy of Sleep Medi-
cine, 2005. 
 29 Sleep-related breathing disorders in adults: 
recommendations for syndrome definition 
and measurement techniques in clinical re-
search. The Report of an American Academy 
of Sleep Medicine Task Force. Sleep 1999; 22: 
 667–689. 
 30 Carskadon MA, Dement WC, Mitler MM, 
Roth T, Westbrook PR, Keenan S: Guidelines 
for the multiple sleep latency test (MSLT): a 
standard measure of sleepiness. Sleep 1986; 
 9: 519–524. 
 31 Sturzenegger C, Bassetti CL: The clinical 
spectrum of narcolepsy with cataplexy: a re-
appraisal. J Sleep Res 2004; 13: 395–406. 
 32 Mignot E, Lammers GJ, Ripley B, et al: The 
role of cerebrospinal f luid hypocretin mea-
surement in the diagnosis of narcolepsy and 
other hypersomnias. Arch Neurol 2002; 59: 
 1553–1562. 
 33 Arnulf I: Excessive daytime sleepiness in 
parkinsonism. Sleep Med Rev 2005; 9: 185–
200. 
 34 Hobson DE, Lang AE, Martin WR, Razmy 
A, Rivest J, Fleming J: Excessive daytime 
sleepiness and sudden-onset sleep in Parkin-
son disease: a survey by the Canadian Move-
ment Disorders Group. JAMA 2002; 287: 
 455–463. 
 35 Bishop C, Rosenthal L, Helmus T, Roehrs T, 
Roth T: The frequency of multiple sleep onset 
REM periods among subjects with no exces-
sive daytime sleepiness. Sleep 1996; 19: 727–
730. 
 36 Singh M, Drake CL, Roth T: The prevalence 
of multiple sleep-onset REM periods in a 
population-based sample. Sleep 2006;  29: 
 890–895. 
 37 Mignot E, Lin L, Finn L, Lopes C, Pluff K, 
Sundstrom ML, Young T: Correlates of sleep-
onset REM periods during the Multiple 
Sleep Latency Test in community adults. 
Brain 2006; 129: 1609–1623. 
 38 Merino-Andreu M, Arnulf I, Konofal E, De-
renne JP, Agid Y: Unawareness of naps in 
Parkinson’s disease and in disorders with ex-
cessive daytime sleepiness. Neurology 2003; 
 60: 1553–1554. 
 39 Bonet M, Moore S: The threshold of sleep: 
perception of sleep as a function of time 
asleep and auditory threshold. Sleep 1982; 5: 
 267–276. 
 40 Tan EK, Lum SY, Fook-Chong SM, et al: 
Evaluation of somnolence in Parkinson’s 
disease: comparison with age- and sex-
matched controls. Neurology 2002; 58: 465–
468. 
 41 Kumar S, Bhatia M, Behari M: Excessive day-
time sleepiness in Parkinson’s disease as as-
sessed by Epworth Sleepiness Scale (ESS). 
Sleep Med 2003; 4: 339–342. 
 42 Braak H, Ghebremedhin E, Rub U, Bratzke 
H, Del Tredici K: Stages in the development 
of Parkinson’s disease-related pathology. 
Cell Tissue Res 2004; 318: 121–134. 
 43 Saper CB, Scammell TE, Lu J: Hypothalamic 
regulation of sleep and circadian rhythms. 
Nature 2005; 437: 1257–1263. 
 44 Lu J, Sherman D, Devor M, Saper CB: A puta-
tive flip-flop switch for control of REM sleep. 
Nature 2006; 441: 589–594. 
 45 Hogl B, Seppi K, Brandauer E, et al: Increased 
daytime sleepiness in Parkinson’s disease: a 
questionnaire survey. Mov Disord 2003; 18: 
 319–323. 
 46 Brodsky MA, Godbold J, Roth T, Olanow 
CW: Sleepiness in Parkinson’s disease: a con-
trolled study. Mov Disord 2003; 18: 668–672. 
 
